Optimal allocation of the limited oral cholera vaccine supply between endemic and epidemic settings

Journal of the Royal Society Interface

Volumn 12, Issue 111, 2015, Pages

  Moore, Sean M ^a   Lessler, Justin ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cholera; Minimax; Reactive vaccination; Vaccine; Vaccine stockpile

Indexed keywords

DISEASES; EPIDEMIOLOGY; OPTIMIZATION;

ALLOCATION STRATEGY; CHOLERA; HEALTH ORGANIZATIONS; MINIMAX; MINIMAX STRATEGY; OPTIMAL ALLOCATION; REACTIVE VACCINATION; VACCINE SUPPLIES;

VACCINES;

CHOLERA VACCINE;

ARTICLE; CHOLERA; ENDEMIC DISEASE; EPIDEMIC; GROWTH RATE; HUMAN; MATHEMATICAL MODEL; RESOURCE ALLOCATION; VACCINATION; COMMUNICABLE DISEASE CONTROL; DISASTER PLANNING; ORAL DRUG ADMINISTRATION; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; SUPPLY AND DISTRIBUTION; THEORETICAL MODEL; TIME FACTOR; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; CHOLERA; CHOLERA VACCINES; COMMUNICABLE DISEASE CONTROL; DISASTER PLANNING; EPIDEMICS; HUMANS; IMMUNIZATION PROGRAMS; MODELS, THEORETICAL; PUBLIC HEALTH; TIME FACTORS; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 84945944390     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2015.0703     Document Type: Article

References (41)

1. Ali M, Lopez AL, Ae You Y, Eun Kim Y, Sah B, Maskery B, Clemens J. 2012 The global burden of cholera. Bull. World Health Organ. 90, 209-218. (doi:10.2471/BLT.11.093427)
2. PAHO. 2013 23 December 2013 Epidemiological update-cholera. See http://www.paho.org/hq/index.php?option=com-content&view=article&id= 9249%3A23-december-2013-epidemiological-update-cholera&catid=2103%3A-hsd0104dmost-recent-ea<emid=3925&lang=en (accessed 28 January 2014).
3. WHO. 2012 Cholera fact sheet. See http://www.who int/mediacentre/factsheets/fs107/en/ (accessed 28 January 2014).
4. WHO. 2010 Cholera vaccines: WHO position paper. Wkly Epidemiol. Rec. 85, 117-128.
5. Martin S, Costa A, Perea W. 2012 Stockpiling oral cholera vaccine. Bull. World Health Organ. 90, 714. (doi:10.2471/BLT.12.112433)
6. WHO. 2012 WHO Technical Working Group on creation of an oral cholera vaccine stockpile. See http://www.who.int/cholera/publications/oral-choIera-vaccine/en/index.htm I (accessed 17 December 2013).
7. GAVI Alliance. 2013 GAVI Alliance to support introduction of inactivated polio vaccine in world's 73 poorest countries-2013-Press releases-News-Library-GAVI Alliance. See http: //www.gavialliance.org/library/news/press-reIeases/2013/gavi-alliance-to-support-introduction-of-inactivated-polio-vaccine-in-worlds-73-poorest-countries/ (accessed 28 January 2014).
8. Mukandavire Z, Liao S, Wang J, Gaff H, Smith DL, Morris JG. 2011 Estimating the reproductive numbers for the 2008-2009 cholera outbreaks in Zimbabwe. Proc. Natl Acad. Sci. USA 108, 8767-8772. (doi:10.1073/pnas.l 019712108)
9. Gaudart J et al. 2013 Spatio-temporal dynamics of cholera during the first year of the epidemic in Haiti. PLoS Negl. Imp. Dis. 7, e2145. (doi:10.1371/ journal.pntd.0002145)
10. Gaffga NH, Tauxe RV, Mintz ED. 2007 Cholera: a new homeland in Africa? Am. J. Trop. Med. Hyg. 77, 705.
11. Chao D, Halloran E, Longini IM. 2011 Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc. Natl Acad. Sci. USA 108, 7081-7085. (doi:10.1073/pnas. 1102149108)
12. Azman AS, Luquero FJ, Rodrigues A, Palma PP, Grais RF, Banga CN, Grenfell BT, Lessler J. 2012 Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from Bissau city, Guinea Bissau. PLoS Negl. Trop. Dis. 6, e1901. (doi:10.1371/journal.pntd.0001901)
13. Manski C. 2011 Choosing treatment policies under ambiguity. Annu. Rev. Icon. 3, 25-49. (doi:10. 1146/annurev-economics-061109-080359)
14. Von Neumann J, Morgenstern O. 1944 Theory of games and economic behavior, vol. xviii. Princeton, NJ: Princeton University Press.
15. Anderson RM, May RM. 1991 Infectious diseases of humans, vol. 1. Oxford, UK: Oxford university press.
16. Codeco C. 2001 Endemic and epidemic dynamics of cholera: the role of the aquatic reservoir. BMC Infect. Dis. 1, 1. (doi:10.1186/1471-2334-1-1)
17. Hartley DM, Smith D. 2005 Hyperinfectivity: a critical element in the ability of V. cholerae to cause epidemics? PLoS Med. 3, e7. (doi:10.1371/journal. pmed.0030007)
18. Feachem R, Miller C, Drasar B. 1981 Environmental aspects of cholera epidemiology. II. Occurrence and survival of Vibrio cholerae in the environment. Trop. Dis. Bull. 78, 865-880.
19. Patel M, Isaacson M. 1989 Survival of Vibrio cholerae in African domestic water storage containers. S. Afr. Med. J. 76, 365-367.
20. Kaper JB, Morris JG, Levine MM. 1995 Cholera. Clin. Microbiol. Rev. 8, 48-86.
21. Koelle K, Rodo X, Pascual M, Yunus M, Mostafa G. 2005 Refractory periods and climate forcing in cholera dynamics. Nature 436, 696-700. (doi:10. 1038/nature03820)
22. Clemens J et al. 1990 Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335, 270-273. (doi:10.1016/ 0140-6736(90)90080-0)
23. Bhattacharya S et al. 2013 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 13, 1050-1056. (doi:10.1016/S1473-3099(13)70273-1)
24. Lucas M et al. 2005 Effectiveness of mass oral cholera vaccination in Beira, Mozambique. H. Engl. J. Med. 352, 757-767. (doi:10.1056/ NEJMoa043323)
25. Sur D et al. 2009 Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 374, 1694-1702. (doi:10.1016/S0140-6736(09)61297-6)
26. van Loon F et al. 1996 Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 14, 162-166. (doi:10.1016/ 0264-410X(95)00122-H)
27. Glass Rl, Svennerholm A-M, Khan MR, Huda S, Huq Ml, Holmgren J. 1985 Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis. 151, 236-242. (doi:10.1093/infdis/151.2.236)
28. Levine MM, Young CR, Hughes TP, O'donnell S, Black RE, Clements ML, Robins-Browne R, Lim Y-L. 1981 Duration of serum antitoxin response following Vibrio cholerae infection in North Americans: relevance for seroepidemiology. Am. J. Epidemiol. 114, 348-354.
29. Epstein P. 1993 Algal blooms in the spread and persistence of cholera. Biosystems 31, 209-221. (doi:10.1016/0303-2647(93)90050-M)
30. Colwell RR, Huq A. 1994 Environmental reservoir of Vibrio cholerae the causative agent of cholera. Ann. NX Acad. Sci. 740, 44-54. (doi:10.1111/j.1749-6632.1994.tb19852.x)
31. Wallinga J, Lipsitch M. 2007 How generation intervals shape the relationship between growth rates and reproductive numbers. Proc. R. Soc. B 274, 599-604. (doi:10.1098/rspb.2006.3754)
32. Tien J, Earn D. 2010 Multiple transmission pathways and disease dynamic in a waterborne pathogen model. Bull. Math. Biol. 72, 1506-1533. (doi:10. 1007/sl1538-010-9507-6)
33. Grad Y, Miller M, Lipsitch JC. 2012 Cholera modeling: challenges to quantitative analysis and predicting the impact of interventions. Epidemiology 23, 523-530. (doi:10.1097/EDE.0b013e318 2572581)
34. Kanungo S et al. 2009 Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 27, 6887-6893. (doi:10.1016/j.vaccine.2009.09.008)
35. Saha A et al. 2011 Safety and immunogenicity study of a killed bivalent (01 and 0139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29, 8285-8292. (doi:10.1016/j.vaccine.2011.08.108)
36. Luquero FJ et al. 2013 First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012. PLoS Negl. Trop. Dis. 7, e2465. (doi:10.1371/journal.pntd.0002465)
37. Seas C, Miranda J, Gil Al, Leon-Barua R, Patz J, Huq A, Colwell RR, Sack RB. 2000 New insights on the emergence of cholera in Latin America during 1991: the Peruvian experience. Am. J. Trop. Med. Hyg. 62, 513-517.
38. Sur D et al. 2011 Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl. Trop. Dis. 5, e1289. (doi:10.1371/journal.pntd. 0001289)
39. Sack D, Sack RB, Nair BG, Siddique A. 2004 Cholera. Lancet 363, 223-233. (doi:10.1016/S0140-6736(03)15328-7)
40. WHO. 2014 Cholera country profiles. See www.who. int/cholera/countries/en/.
41. Martin S et al. 2014 Post-licensure deployment of oral cholera vaccines: a systematic review. Bull. World Health Organ. 92, 881-893. (doi:10.247V BLT.14.139949)